Welcome to our dedicated page for RELMADA THERAPEUTICS SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics (RLMD) priced an underwritten equity offering of 40,142,000 common shares at $2.20 per share and pre-funded warrants to purchase up to 5,315,000 shares at $2.199 per warrant. The company expects approximately $100 million in net proceeds after underwriting discounts and expenses.
Pre-funded warrants are immediately exercisable at an exercise price of $0.001 per share, with a beneficial ownership cap of 9.99% (or 4.99% at the purchaser’s election). Company insiders, including the CEO, CFO, and other officers and directors, will purchase about $2.6 million of common stock at the same price as other investors.
Relmada plans to use proceeds for working capital and general corporate purposes, including clinical studies to gain regulatory approvals, further product development, licensing, and potential investments or acquisitions. The company agreed to customary indemnification provisions and 90-day restrictions on issuing additional equity or convertible securities.
Relmada Therapeutics (RLMD) launched a primary offering of 40,142,000 shares of common stock at $2.20 per share and pre-funded warrants for 5,315,000 shares, together with 5,315,000 shares issuable upon exercise of those pre-funded warrants. Gross proceeds are $100,000,085, with underwriting discounts of $6,000,324 and proceeds before expenses of $93,999,761; the company estimates net proceeds of approximately $93.7 million.
Relmada plans to use the funds for working capital and general corporate purposes, including clinical studies and development of product candidates. Pre-funded warrants are immediately exercisable at $0.001 per share, with an ownership cap of 9.99% (or 4.99% at the holder’s election). Certain officers indicated interest in up to about $2.6 million of shares at the offering price, which is non-binding. Shares outstanding would be 73,333,622 immediately after the offering, assuming no exercise of pre-funded warrants. As of October 24, 2025, shares outstanding were 33,191,622.
Relmada Therapeutics (RLMD) reported FDA feedback on its proposed Phase III program for NDV-01 in non-muscle invasive bladder cancer and shared nine-month Phase II safety and efficacy data. The FDA indicated a single-arm trial may be acceptable in BCG‑unresponsive patients refractory to other therapies, and a randomized post‑TURBT adjuvant study versus observation in intermediate‑risk NMIBC with a time‑to‑event primary endpoint is generally acceptable, subject to submission of the intended designs. The company plans to request Type B meetings.
In Phase II high‑risk NMIBC, NDV‑01 showed no Grade ≥3 treatment‑related adverse events among 36 patients; 61% had treatment‑related adverse events, primarily transient dysuria (62%), asymptomatic positive urine culture (9%), and hematuria (7%). Complete response rates were 92% (anytime; 23/25), 84% at 3 months (21/25), 87% at 6 months (20/23), and 85% at 9 months (17/20), with two of two patients in CR at 12 months. Relmada expects approximately $13.9 million in cash, cash equivalents and short‑term investments as of September 30, 2025.
Relmada Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on September 17, 2025. The updated presentation is provided as Exhibit 99.1 and is incorporated by reference into the Regulation FD disclosure section of the report.
The company states that this information, including Exhibit 99.1, is being furnished under Regulation FD and is not deemed filed for purposes of certain liability provisions of the federal securities laws. No financial results, transactions, or other operational changes are described in this excerpt beyond the availability of the new corporate presentation.
Relmada Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement. The company received a written notice of compliance from Nasdaq’s Listing Qualifications Department stating that, for 10 consecutive trading days from August 29, 2025 to September 12, 2025, the closing bid price of its common stock was at or above $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2).
Nasdaq informed Relmada that it now considers the listing compliance matter closed, meaning the company’s common stock remains listed on the Nasdaq Capital Market under the symbol RLMD. Relmada issued a press release on September 15, 2025 to communicate this development, which is referenced as an exhibit in the filing.
Relmada Therapeutics, Inc. filed a current report to share updated communications with investors. On September 10, 2025, the company issued a letter to shareholders describing its recent progress, which is furnished as Exhibit 99.1. On the same date, Relmada also updated its corporate presentation, furnished as Exhibit 99.2. The company notes that these materials are provided under Regulation FD and are considered "furnished" rather than "filed" under securities laws, meaning they are not automatically incorporated into other SEC filings unless specifically referenced.
Relmada Therapeutics reported that its Chief Medical Officer-Urology, Raj S. Pruthi, MD, purchased 55,000 shares of the Company’s common stock in open market transactions on August 29, 2025. This insider purchase reflects a direct acquisition of additional equity by a senior executive using the public market rather than through company grants or option exercises. The disclosure is provided under Regulation FD as furnished information, meaning it is not treated as filed under certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
Sergio Traversa, CEO and Director of Relmada Therapeutics, Inc. (RLMD), reported open-market purchases totaling 265,976 shares across three days, increasing his beneficial ownership to 1,000,000 shares. The Form 4 shows purchases on 08/26/2025 (80,545 shares at a weighted-average price of $0.62), 08/27/2025 (129,455 shares at $0.67), and 08/28/2025 (55,976 shares at $0.74). The filing explains each line represents aggregated open-market trades executed over price ranges: $0.61–$0.65, $0.65–$0.69, and $0.68–$0.79 respectively. All reported holdings are direct and the form is signed by the reporting person.
Schedule 13G/A filed for Relmada Therapeutics (RLMD) discloses beneficial ownership stakes held by Squadron-related filers. Squadron Master Fund LP reports shared beneficial ownership of 2,914,495 shares representing 8.8% of the outstanding common stock. Squadron Capital Management LLC and William Blank each report shared beneficial ownership of 3,298,500 shares, representing 9.9% of the class. The filing clarifies that Squadron Capital Management serves as adviser to funds that hold these shares and that Mr. Blank may be deemed to have investment and voting discretion, while expressly disclaiming beneficial ownership under Rule 13d-4. The ownership percentages are calculated using an issuer-stated share count of 33,191,622 shares outstanding.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) filed a Form 8-K on 7-Aug-2025 announcing Item 2.02 (Results of Operations) and Item 7.01 (Reg FD).
- The company furnished, but did not file, a press release (Ex. 99.1) containing a corporate update and preliminary, unaudited Q2 2025 results for the period ended 30-Jun-2025.
- A conference call and webcast are scheduled for 7-Aug-2025 at 4:30 PM EDT to discuss the update.
- Full unaudited financial statements will appear in the forthcoming Form 10-Q.
- An updated corporate presentation (Ex. 99.2) was also furnished.
- No quantitative financial metrics, guidance, or transactional details are included in the 8-K itself; all figures reside in the referenced exhibits.
The furnished information is not deemed “filed” under the Exchange Act and therefore carries reduced liability. Investors must consult Exhibits 99.1 and 99.2 or the upcoming 10-Q for substantive financial data.